Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor Immunotherapy Study
NCT04448509 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2020-06-26
Summary
Peripheral blood mononuclear cell collection protocol for tumor immunotherapy study of UCAR-T cells
Conditions
- Peripheral Blood Mononuclear Cell
Interventions
- OTHER
-
Peripheral blood mononuclear cell apheresis
Peripheral blood mononuclear cell collection for tumor immunotherapy study of UCAR-T cells
Sponsors & Collaborators
-
Nanjing Bioheng Biotech Co., Ltd.
collaborator INDUSTRY -
He Huang
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-06-18
- Primary Completion
- 2020-07-18
- Completion
- 2022-08-31
Countries
- China
Study Locations
More Related Trials
-
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
NCT05528887 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
NCT04227015 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)
NCT04803929 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies
NCT04662788 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
NCT04283006 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
NCT04532268 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
NCT04532281 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies
NCT05239689 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors
NCT06849921 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
NCT04658004 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Universal CAR-γδT Cell Injection in the AML Patients
NCT05388305 ·Status: UNKNOWN ·Phase: NA
-
Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors
NCT04665076 ·Status: UNKNOWN ·Phase: NA
-
CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML
NCT02944162 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma
NCT06676982 ·Status: RECRUITING ·Phase: PHASE1
-
A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma
NCT04665063 ·Status: UNKNOWN ·Phase: NA
-
Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children
NCT04610125 ·Status: UNKNOWN ·Phase: NA
-
CAR-T Cells in the Treatment of Malignant Hematological Tumors
NCT05619861 ·Status: UNKNOWN ·Phase: NA
-
A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)
NCT04933825 ·Status: UNKNOWN ·Phase: NA
-
Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma
NCT06461624 ·Status: RECRUITING ·Phase: PHASE1
-
Universal 4SCAR7U Targeting CD7-positive Malignancies
NCT05995028 ·Status: RECRUITING ·Phase: PHASE1
-
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
NCT04662294 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies
NCT04657965 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
NCT03121625 ·Status: UNKNOWN ·Phase: PHASE1
-
PSMA-specific CAR-T Cell Therapy
NCT04429451 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma
NCT04626908 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2